This exclusive licence agreement gives GSK rights to commercialize Brexafemme for vulvovaginal candidiasis and recurrent VVC while continuing to develop ibrexafungerp, which is in phase III clinical trials for the potential treatment of invasive candidiasis (IC), a life-threatening fungal infection.
Tag Archive for: GSK
The company has signed deals with three companies allowing them to make inexpensive generic versions of its long-acting HIV preventive medicine for use in lower-income countries, where the majority of new HIV cases occur.
Pfizer Inc and GSK are close to bringing the first two vaccines for RSV to the United States after gaining the backing of a panel of advisers to the FDA.
The company is discontinuing the late-stage study of its experimental respiratory syncytial virus adult vaccine, weeks after rivals Pfizer and GSK gained a lead in the race for the first vaccine against the virus.
Merck’s Keytruda appeared to outperform GSK’s Jemperli in a key endometrial cancer patient subgroup, suggesting late-stage data revealed Monday during the Society of Gynecologic Oncology 2023 Annual Meeting.
A California judge’s decision to allow expert testimony linking GSK’s heartburn drug Zantac to cancer wasn’t a surprise, analysts said, though the litigation will likely weigh on the drugmaker’s share price until a trial in the summer.
Executives at three vaccine manufacturers – GSK, Moderna, and CSL Seqirus told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.
GSK’s chief scientist says an overhaul of the drugmaker’s R&D unit has begun delivering results and pledged a tighter focus than his predecessor on infectious disease and HIV.
If approved, the combo vaccine could simplify the immunization schedule in the United States and likely expand GSK’s already dominant market share there for vaccines used to prevent illnesses caused by meningococcal bacteria.
GSK expects to launch its respiratory syncytial virus (RSV) vaccine in the U.S. this year without supply constraints and sees China as a major future market for the shot, a senior executive told Reuters.
